| RAMLAU, Rodryg, Tanja CUFER, Peter BERZINEC, Rafal DZIADZIUSZKO, Wlodzimier OSLZEWSKI, Helmut POPPER, Paolo BAJCIC, Ladislav DUŠEK, Zuzana ZBOŽÍNKOVÁ a Robert PIRKER. Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe The INSIGHT Study. Journal of Thoracic Oncology. Philadelphia: Lippincott Williams & Wilkins, 2015, roč. 10, č. 9, s. 1370-1374. ISSN 1556-0864. Dostupné z: https://dx.doi.org/10.1097/JTO.0000000000000621. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1312075,
author = {Ramlau, Rodryg and Cufer, Tanja and Berzinec, Peter and Dziadziuszko, Rafal and Oslzewski, Wlodzimier and Popper, Helmut and Bajcic, Paolo and Dušek, Ladislav and Zbožínková, Zuzana and Pirker, Robert},
article_location = {Philadelphia},
article_number = {9},
doi = {http://dx.doi.org/10.1097/JTO.0000000000000621},
keywords = {Targeted therapy; INSIGHT; EGFR mutations; Molecular analysis},
language = {eng},
issn = {1556-0864},
journal = {Journal of Thoracic Oncology},
title = {Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe The INSIGHT Study},
volume = {10},
year = {2015}
}
TY - JOUR
ID - 1312075
AU - Ramlau, Rodryg - Cufer, Tanja - Berzinec, Peter - Dziadziuszko, Rafal - Oslzewski, Wlodzimier - Popper, Helmut - Bajcic, Paolo - Dušek, Ladislav - Zbožínková, Zuzana - Pirker, Robert
PY - 2015
TI - Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe The INSIGHT Study
JF - Journal of Thoracic Oncology
VL - 10
IS - 9
SP - 1370-1374
EP - 1370-1374
PB - Lippincott Williams & Wilkins
SN - 15560864
KW - Targeted therapy
KW - INSIGHT
KW - EGFR mutations
KW - Molecular analysis
N2 - The ImplementatioN of perSonalized medicine In NSCLC in Central Europe: EGFR testing, Histopathology, and clinical feaTures (INSIGHT) observational study assessed both implementation of epidermal growth factor receptor (EGFR) mutation testing and treatment of patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC) in a real-world setting in Central Europe. A total of 1785 patients from 14 cancer centers of six Central European countries were enrolled. EGFR mutations were detected in tumors of 13.8% of the patients. More than 70% of patients with advanced EGFR mutation-positive NSCLC received EGFR tyrosine kinase inhibitors as first-line therapy. The INSIGHT study demonstrated the establishment of EGFR mutation testing, a mutation rate consistent with other Caucasian patients populations, and adherence to current guidelines regarding treatment of patients with EGFR mutation-positive tumors in Central Europe.
ER -
RAMLAU, Rodryg, Tanja CUFER, Peter BERZINEC, Rafal DZIADZIUSZKO, Wlodzimier OSLZEWSKI, Helmut POPPER, Paolo BAJCIC, Ladislav DUŠEK, Zuzana ZBOŽÍNKOVÁ a Robert PIRKER. Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe The INSIGHT Study. \textit{Journal of Thoracic Oncology}. Philadelphia: Lippincott Williams \&{} Wilkins, 2015, roč.~10, č.~9, s.~1370-1374. ISSN~1556-0864. Dostupné z: https://dx.doi.org/10.1097/JTO.0000000000000621.
|
